JPRN-jRCT2071210022已完成1 期
Clinical Pharmacology Study of EPI-589 (DA301006)
Hamatani Tatsuto0 个研究点目标入组 68 人开始时间: 2021年5月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •1) Healthy male Japanese or Caucasian subjects between 20 and 55 years of age (inclusive) at the time of consent.
- •2) Subject who was fully informed and understood the objectives, procedures, anticipated drug effects/pharmacological action and risks of the study and who voluntarily provided written consent to participate in the study.
- •3) Subject's body weight was between 50.0 and 80.0 kg (Japanese) and 50.0 and 100.0 kg (Caucasian), and body mass index (BMI) was at least 16 kg/m2 but no more than 32 kg/m2 at Screening.
- •4) Subject who was able to comply with the study requirements, including physical examination, assessments, and reporting symptoms.
- •5) Subject with female partners of childbearing potential practiced abstinence, consistent with lifestyle or acceptable birth control from the time of signing informed consent until at least 30 days after the last study drug administration.
- •6) Subject possessed an educational level and degree of understanding of English or Japanese that enabled him to communicate suitably with the Investigators and study coordinator.
排除标准
- •1) Subject with a history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, psychiatric, or neurologic disease, and who were considered ineligible for the study by the Investigator.
- •2) Subject with a clinically significant abnormal 12-lead ECG that may have jeopardized the subject's ability to complete the study or a Screening 12-lead ECG that demonstrated any 1 of the following: heart rate > 100 beats per minute, QT interval corrected for heart rate using Fridericia correction > 450 msec.
- •3) Subject who had a history of drug allergy.
- •4) Subject with any allergy or hypersensitivity to Coenzyme Q10 or Vitamin E supplements.
- •5) Subject with a history of substance abuse including alcohol and drugs, or a positive urine drug test at Screening.
- •6) Subject who had a positive immunology at Screening [Hepatitis B surface antigen, Hepatitis C virus antibody, syphilis serological testing, human immunodeficiency virus antibody/antigen].
- •7) Subject with any clinically significant abnormal physical examination, clinical laboratory values, vital signs, and 12-lead ECG findings at Screening.
- •8) Subject who was abusing or suspected to be abusing alcohol.
- •9) Subject who ordinarily consumed large quantities of caffeinated beverages (coffee, tea, green tea, cola, tonic drink, etc).
- •10) Subject with a history of tobacco dependency or subject who smoked a mean of more than 20 cigarettes daily.
- •11) Subject who previously received EPI-589.
- •12) Subject who had participated in an investigational drug study and received any investigational drug within 90 days prior to Screening, or who was participating in another clinical study during the conduct of this study.
- •13) Subject who had experienced significant blood loss or donated blood (> 400 mL) within 90 days or donated 200 mL of blood or more within 30 days prior to the initial study drug administration (Day 1). Subject who had donated blood components within 14 days prior to the initial study drug administration (Day 1) or intended to donate blood components or blood within 30 days after the last study visit.
- •14) Subject with a history of hospitalization (except for hospitalization for tests) within 45 days prior to Screening.
- •15) Subject with a disorder or history of a condition (such as malabsorption and gastrointestinal surgery) that may have interfered with drug absorption, distribution, metabolism, or excretion, or a clinically significant abnormality of the hepatic or renal system.
- •16) Subject who had consumed coenzyme Q10 or Vitamin E supplements within 14 days prior to the initial study drug administration (Day 1).
- •17) Subject who had consumed St. John's wort-containing foods or beverages within 14 days prior to the initial study drug administration (Day 1).
- •18) Subject who had consumed grapefruit or grapefruit-containing juices within 7 days prior to the initial study drug administration (Day 1).
- •19) Subject who had used prescription or over-the-counter medications within 14 days prior to the initial study drug administration (Day 1).
- •20) Subject who had consumed alcohol on the day before Screening or thereafter and 2 days before the initial study drug administration (Day 1) and thereafter.
- •21) Subject who was in the opinion of the Investigators unsuitable in any other way to participate in this study.
研究者
相似试验
招募中
1 期
Clinical Pharmacology Study of EPI-589Amyotrophic lateral sclerosisJPRN-jRCT2071210023Hamatani Tatsuto40
进行中（未招募）
1 期
Formulation Pharmacokinetics Study of EPI-589JPRN-jRCT2071220047Hamatani Tatsuto24
进行中（未招募）
1 期
A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease.Parkinson’s diseaseMedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2015-001786-10-DEBioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)40
进行中（未招募）
1 期
A clinical study of the effects of EPI-589 on safety and indicators of oxidative stress in patients with Parkinson's disease.Parkinson’s diseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-001786-10-GBBioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)40
已完成
2 期
Clinical Pharmacology Study of Z-206 - Study on Drug Concentration in Mucous Membrane of Z-206 in Healthy Male Adultslcerative ColitisJPRN-UMIN000000678Zeria Pharmaceutical Co., LTD.36